Since hypoxia is a key feature of ON, we might expect that downstream effectors of HIF-1α, like VEGF or other angiogenic or metabolic agents could be of value in the diagnosis, progression and therapy of bone diseases like osteonecrosis. Here, VEGFA is linked to osteonecrosis.